Literature DB >> 31363847

A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.

Hernan Inojosa1, Undine Proschmann1, Katja Akgün1, Tjalf Ziemssen2.   

Abstract

Secondary progressive multiple sclerosis (SPMS) is the second most common form of multiple sclerosis (MS). One in two relapse remitting multiple sclerosis (RRMS) patients will develop SPMS within 15 years and up to two-thirds after 30 years, leading to a progressive decrease of neurological function and limitation of daily activities. Nevertheless, the SPMS diagnosis is often established retrospectively and delayed up to 3 years due to several patient- and clinician-related factors. Definitive clinical diagnostic criteria are lacking and research is currently ongoing to identify imaging and biochemical biomarkers. As new therapies are introduced, early SPMS diagnosis may represent a window of opportunity for intervention. New approaches, endpoints or technologies could help physicians establishing a diagnosis. Here, we review SPMS in relation to its diagnostic and definition challenges and current screening techniques and tools.

Entities:  

Keywords:  Definition; Diagnosis; Endpoints; SPMS; Screening

Mesh:

Year:  2019        PMID: 31363847     DOI: 10.1007/s00415-019-09489-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  54 in total

Review 1.  New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

Authors:  Clayton English; Joseph J Aloi
Journal:  Clin Ther       Date:  2015-04-04       Impact factor: 3.393

2.  Onset of secondary progressive phase and long-term evolution of multiple sclerosis.

Authors:  Antonio Scalfari; Anneke Neuhaus; Martin Daumer; Paolo Antonio Muraro; George Cornell Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-13       Impact factor: 10.154

3.  The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences.

Authors:  Freya Davies; Fiona Wood; Katherine E Brain; Michelle Edwards; Rhiannon Jones; Rachel Wallbank; Neil P Robertson; Adrian Edwards
Journal:  Int J MS Care       Date:  2016 Sep-Oct

4.  fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis.

Authors:  Caterina Mainero; Francesca Caramia; Carlo Pozzilli; Angela Pisani; Isabella Pestalozza; Giovanna Borriello; Luigi Bozzao; Patrizia Pantano
Journal:  Neuroimage       Date:  2004-03       Impact factor: 6.556

Review 5.  Relapsing and progressive forms of multiple sclerosis: insights from pathology.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

6.  Brain reserve and cognitive reserve in multiple sclerosis: what you've got and how you use it.

Authors:  James F Sumowski; Maria A Rocca; Victoria M Leavitt; Gianna Riccitelli; Giancarlo Comi; John DeLuca; Massimo Filippi
Journal:  Neurology       Date:  2013-05-10       Impact factor: 9.910

Review 7.  Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach.

Authors:  Tjalf Ziemssen; Raimar Kern; Katja Thomas
Journal:  BMC Neurol       Date:  2016-08-02       Impact factor: 2.474

8.  Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.

Authors:  Francisco Coret; Francisco C Pérez-Miralles; Francisco Gascón; Carmen Alcalá; Arantxa Navarré; Ana Bernad; Isabel Boscá; Matilde Escutia; Sara Gil-Perotin; Bonaventura Casanova
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-06-26

9.  Neurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis.

Authors:  Mariana López-Góngora; Antonio Escartín; Saul Martínez-Horta; Ramón Fernández-Bobadilla; Luis Querol; Sergio Romero; Miquel Àngel Mañanas; Jordi Riba
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

10.  Long-term evolution of multiple sclerosis disability in the treatment era.

Authors:  Bruce A C Cree; Pierre-Antoine Gourraud; Jorge R Oksenberg; Carolyn Bevan; Elizabeth Crabtree-Hartman; Jeffrey M Gelfand; Douglas S Goodin; Jennifer Graves; Ari J Green; Ellen Mowry; Darin T Okuda; Daniel Pelletier; H-Christian von Büdingen; Scott S Zamvil; Alisha Agrawal; Stacy Caillier; Caroline Ciocca; Refujia Gomez; Rachel Kanner; Robin Lincoln; Antoine Lizee; Pamela Qualley; Adam Santaniello; Leena Suleiman; Monica Bucci; Valentina Panara; Nico Papinutto; William A Stern; Alyssa H Zhu; Gary R Cutter; Sergio Baranzini; Roland G Henry; Stephen L Hauser
Journal:  Ann Neurol       Date:  2016-08-13       Impact factor: 10.422

View more
  21 in total

Review 1.  Toxic Air Pollutants and Their Effect on Multiple Sclerosis: A Review Study.

Authors:  Mohammad Javad Mohammadi; Kourosh Zarea; Nasser Hatamzadeh; Arash Salahshouri; Asaad Sharhani
Journal:  Front Public Health       Date:  2022-07-06

Review 2.  Stem Cell Therapies for Progressive Multiple Sclerosis.

Authors:  Jayden A Smith; Alexandra M Nicaise; Rosana-Bristena Ionescu; Regan Hamel; Luca Peruzzotti-Jametti; Stefano Pluchino
Journal:  Front Cell Dev Biol       Date:  2021-07-09

3.  A cross-sectional study of alexithymia in patients with relapse remitting form of multiple sclerosis.

Authors:  J Stojanov; A Stojanov
Journal:  J Postgrad Med       Date:  2020 Jan-Mar       Impact factor: 1.476

Review 4.  Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives.

Authors:  Elisabeth G Celius; Heidi Thompson; Maija Pontaga; Dawn Langdon; Alice Laroni; Stanca Potra; Trishna Bharadia; David Yeandle; Jane Shanahan; Pieter van Galen; Nektaria Alexandri; Jürg Kesselring
Journal:  Patient Prefer Adherence       Date:  2021-01-08       Impact factor: 2.711

Review 5.  Should We Use Clinical Tools to Identify Disease Progression?

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  Front Neurol       Date:  2021-01-21       Impact factor: 4.003

6.  N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis.

Authors:  Fei Ye; Tianzhu Wang; Xiaoxin Wu; Jie Liang; Jiaoxing Li; Wenli Sheng
Journal:  J Transl Med       Date:  2021-07-22       Impact factor: 5.531

7.  Dry needling for treating spasticity in multiple sclerosis.

Authors:  María Del Pilar Pérez-Trujillo; Montserrat González-Platas; María Yaiza Pérez-Martín; María Consuelo Revert-Gironés; Javier González-Platas
Journal:  J Phys Ther Sci       Date:  2021-07-01

8.  Wearable sensors can reliably quantify gait alterations associated with disability in people with progressive multiple sclerosis in a clinical setting.

Authors:  Lorenza Angelini; William Hodgkinson; Craig Smith; Jessie Moorman Dodd; Basil Sharrack; Claudia Mazzà; David Paling
Journal:  J Neurol       Date:  2020-05-28       Impact factor: 4.849

9.  Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2020-10-27       Impact factor: 5.749

10.  The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice.

Authors:  Katrin Trentzsch; Marie Luise Weidemann; Charlotte Torp; Hernan Inojosa; Maria Scholz; Rocco Haase; Dirk Schriefer; Katja Akgün; Tjalf Ziemssen
Journal:  Front Neurosci       Date:  2020-10-26       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.